A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111366 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hong He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Melbourne, Studley Road, Heidelberg, VIC 3084, Australia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Gemcitabine, Cell Proliferation. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Phebra Ltd Pty, Phebra Pty. Ltd., Pancare Foundation.
Abstract (Originalsprache)
Arsenic trioxide (ATO) has been shown to inhibit pancreatic cancer (PC) cell growth in vitro and to promote the inhibitory effects of gemcitabine (Gem) on PC in vivo. However, the high toxicity of ATO associated with the required high doses and indiscriminate targeting has limited its clinical application. This study aimed to determine whether coupling arsenic to a tumor homing peptide would increase the inhibitory potency against PC cells. The effects of this peptide-linked arsenic compound (PhAs-LHP), the analogous non-targeting arsenic compound (phenylarsine oxide, PAO), and marketed ATO on PC growth were tested in vitro and in a mouse model. The data demonstrated that PhAs-LHP inhibited PC cell growth in vitro more potently, with IC50 values 10 times lower than ATO. Like ATO, PhAs-LHP induced cell death and cell cycle arrest. This cytotoxic effect of PhAs-LHP was mediated via a macropinocytosis-linked uptake pathway as amiloride (a macropinocytosis inhibitor) reduced the inhibitory effect of PhAs-LHP. More importantly, PhAs-LHP inhibited PC growth in mice and enhanced the inhibitory effect of Gem on PC growth at 2 times lower molar concentration than PAO. These results indicate that PhAs-LHP inhibited PC more potently than ATO/PAO and suggest a potential clinical use for the combination of Gem with the peptide-linked arsenic compound for the treatment of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Melbourne, Studley Road, Heidelberg, VIC 3084, Australia.
- School of Chemistry and Molecular Bioscience, University of Wollongong, Sydney, NSW 2522, Australia.
- Phebra Pty. Ltd., Lane Cove West, Sydney, NSW 2066, Australia.
ORCID-Profile: Hong He, Judith A Carrall, Li Dong
Förderung
- Phebra Ltd Pty
- Phebra Pty. Ltd.
- Pancare Foundation
Zitieren
APA
He, H., Dumesny, C., Carrall, J. A., Dillon, C. T., de Roo, K. I., Eutick, M., Dong, L., Baldwin, G. S., & Nikfarjam, M. (2024). A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111366
Vancouver
He H, Dumesny C, Carrall JA, Dillon CT, de Roo KI, Eutick M, et al. A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111366
BibTeX
@article{He2024,
author = {He, Hong and Dumesny, Chelsea and Carrall, Judith A and Dillon, Carolyn T and de Roo, Katja I and Eutick, Mal and Dong, Li and Baldwin, Graham S and Nikfarjam, Mehrdad},
title = {A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111366}
}
EUVIMED